NPPA has fixed retail prices of 14 formulations under Drugs Prices Control Order (DPCO)- 2013 relating to 76th Authority meeting dated June 22, 2020.

Name of the formulations include clopidogrel bisulphate + aspirin tablet, glimepiride + metformin hydrochloride tablet, atorvastatin + aspirin capsule, cilnidipine + telmisartan tablet (Telsartan –LN 80), cilnidipine + telmisartan tablet (Telsartan –LN 40), rosuvastatin + aspirin + clopidogrel capsule, rosuvastatin + aspirin + clopidogrel capsule (Rozat Gold 20mg), glimepiride + metformin hydrochloride tablet (Glimy M3 Forte), glimepiride + metformin hydrochloride tablet (Glimy M4 Forte), etoricoxib + paracetamol tablet, tolperisone hydrochloride + diclofenac sodium tablet and cilnidipine + metoprolol tablet.

The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.

The retail price for a pack of the these formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO -2013.